MM13598 - National Coverage Determination 200.3: Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
This revised Article comprises Subregulatory Guidance to Make sure your billing staffs knows about: FDA-approved monoclonal antibodies, Criteria for coverage, Coding information, Claims processing instructions. MLN Matters (MM) Articles are based on information contained within Change Requests (CRs). In this case, this article is based on content within CR13598 that is posted on the CMS website at https://www.cms.gov/files/document/r12649CP.pdf
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: May 24, 2024
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.